JPMorgan raised the firm’s price target on RxSight (RXST) to $9 from $8 and keeps an Underweight rating on the shares. The company’s Q3 report cleared a low bar but its growth outlook remains uncertain, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXST:
- RxSight’s Strong Q3 Performance and Strategic Initiatives Justify Buy Rating
- RxSight, Inc. Reports Q3 2025 Financial Results
- RxSight reports Q3 EPS (4c), consensus (23c)
- RxSight sees FY25 revenue $125M-$130M vs. prior view $120M-$130M
- Needham medtech & diagnostics analysts hold analyst/industry conference call